Previous close | 10.89 |
Open | 11.00 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's range | 10.99 - 11.21 |
52-week range | 10.66 - 16.60 |
Volume | |
Avg. volume | 922,909 |
Market cap | 39.497B |
Beta (5Y monthly) | 0.07 |
PE ratio (TTM) | 19.56 |
EPS (TTM) | 0.57 |
Earnings date | N/A |
Forward dividend & yield | 0.48 (4.34%) |
Ex-dividend date | 11 Apr 2024 |
1y target est | 12.50 |
Zaven Boyrazian explores what’s happening with the collapsing Reckitt Benckiser share price and whether now's the time to buy the FTSE 100 stock. The post Should I rush to buy this FTSE 100 giant currently near its 52-week low? appeared first on The Motley Fool UK.
Consumer goods giant Reckitt has suffered a £7bn share price slump after it lost a US legal case claiming its baby formula contributed to the death of a premature child.
Reckitt said on Monday that many cases had been filed against baby formula makers in general, and it was unclear how many directly related to its unit's Enfamil product. An Illinois jury last week ordered Reckitt unit Mead Johnson to pay $60 million to the mother of a premature baby who died of an intestinal disease after being fed the company's Enfamil baby formula. The jury in a state court in St. Clair County found Mead Johnson was negligent and had failed to warn of the risk of necrotising enterocolitis (NEC).